Cell Communication and Signaling (Oct 2024)

Mitochondrion-based organellar therapies for central nervous system diseases

  • Mengke Zhao,
  • Jiayi Wang,
  • Shuaiyu Zhu,
  • Meina Wang,
  • Chong Chen,
  • Liang Wang,
  • Jing Liu

DOI
https://doi.org/10.1186/s12964-024-01843-z
Journal volume & issue
Vol. 22, no. 1
pp. 1 – 38

Abstract

Read online

Abstract As most traditional drugs used to treat central nervous system (CNS) diseases have a single therapeutic target, many of them cannot treat complex diseases or diseases whose mechanism is unknown and cannot effectively reverse the root changes underlying CNS diseases. This raises the question of whether multiple functional components are involved in the complex pathological processes of CNS diseases. Organelles are the core functional units of cells, and the replacement of damaged organelles with healthy organelles allows the multitargeted and integrated modulation of cellular functions. The development of therapies that target independent functional units in the cell, specifically, organelle-based therapies, is rapidly progressing. This article comprehensively discusses the pathogenesis of mitochondrial homeostasis disorders, which involve mitochondria, one of the most important organelles in CNS diseases, and the machanisms of mitochondrion-based therapies, as well as current preclinical and clinical studies on the efficacy of therapies targeting mitochondrial to treat CNS diseases, to provide evidence for use of organelle-based treatment strategies in the future. Graphical Abstract

Keywords